As Drano pointed out in his post #62196, there is a huge need and demand for a safe and effective IBD drug that can be targeted to any location in the GI tract. This market is projected to be $48B about the time B-IBD pill delivery is available on the market and Brilacidin could secure a very large percentage of this huge market. With this successful Phase 1 study, Brilacidin again showed to be safe and the BDD technology worked exactly as advertised.
Big Pharma (BP) knows this so their decision is to either lock up the exclusive rights NOW before one of their competitors beats them to the punch or to risk losing a huge market and revenue opportunity and wait for a completed phase 2. Remember that Brilacidin has already been proven to be both safe and effective in Phase 2 studies for 3 other instances and 3 other delivery systems.
What is B-IBD pill worth once it is available and producing royalties? If you do some simple napkin math it looks something like this:
Assume a 12% royalty from a BP partner. Assume 250M outstanding shares. Assume a tiny market share of only 4%-10% or a range of $2B-$5B (it could be multiple of this low estimate). Assume a very low PE ratio of 20 (many Bio’s share price (SP) are 3 figures + with no earnings.) Assume IPIX expense of $30M per year (currently around $10M/year).
$2B-$5B revenue x 12% royalty = $240M-$600M royalty revenue
Less $30M expense = $210M-$570M Earnings
$210M-$570M divided by 250M OS = $.84- $2.28 per share earnings.
$.84- $2.28 x 20 PE = a range of $16.8 to $45.6 per Share
This napkin math applies ONLY to B-IBD pill and does not consider the enormous value of B-OM, B-IBD Proctitis (Alfasigma) or other potential Brilacidin applications. It also does not include the enormous potential of Kevetrin which could dwarf Brilacidin revenue if it made it to market.
Not only is BP well aware of the above revenue opportunities but the criminals/NR are aware as well. They have tried and failed to put IPIX out of business and they are exposed with Naked Share Sale (NSS) somewhere in the 40M+ share range. This is an impossible number to know exactly today but it will show itself in SP expansion when NR has to unwind their position. In the short term the criminals continue to control IPIX share price and will keep IPIX SP compressed and severely undervalued. They will also continue to show fake volume. NR needs REAL shares so they will continue to try to get Longs to sell cheap. Remember the Shareholder Meeting vote of 140M yes votes or 90% of voted shares. This number is a proof point that a vast majority of IPIX investors are long and strong. They believe in IPIX’s products and direction and long term value. This proof point highlights the bogus volume that NR is trying to show. You need buyers AND sellers to complete a legit transaction. There are very few sellers so NR must continue to play their criminal games. Once Leo secures non-dilutive funding it is the start of Game-Over for the criminals. Once royalty revenue flows it is the END of the game for the criminals. In the meantime Long Term Investors will enjoy the ride knowing that short term SP is a mirage and our patience will be greatly rewarded as IPIX science continues to advance and milestones are met. Long term there will be great wealth for patient investors.
Big Pharma (BP) knows this so their decision is to either lock up the exclusive rights NOW before one of their competitors beats them to the punch or to risk losing a huge market and revenue opportunity and wait for a completed phase 2. Remember that Brilacidin has already been proven to be both safe and effective in Phase 2 studies for 3 other instances and 3 other delivery systems.
What is B-IBD pill worth once it is available and producing royalties? If you do some simple napkin math it looks something like this:
Assume a 12% royalty from a BP partner. Assume 250M outstanding shares. Assume a tiny market share of only 4%-10% or a range of $2B-$5B (it could be multiple of this low estimate). Assume a very low PE ratio of 20 (many Bio’s share price (SP) are 3 figures + with no earnings.) Assume IPIX expense of $30M per year (currently around $10M/year).
$2B-$5B revenue x 12% royalty = $240M-$600M royalty revenue
Less $30M expense = $210M-$570M Earnings
$210M-$570M divided by 250M OS = $.84- $2.28 per share earnings.
$.84- $2.28 x 20 PE = a range of $16.8 to $45.6 per Share
This napkin math applies ONLY to B-IBD pill and does not consider the enormous value of B-OM, B-IBD Proctitis (Alfasigma) or other potential Brilacidin applications. It also does not include the enormous potential of Kevetrin which could dwarf Brilacidin revenue if it made it to market.
Not only is BP well aware of the above revenue opportunities but the criminals/NR are aware as well. They have tried and failed to put IPIX out of business and they are exposed with Naked Share Sale (NSS) somewhere in the 40M+ share range. This is an impossible number to know exactly today but it will show itself in SP expansion when NR has to unwind their position. In the short term the criminals continue to control IPIX share price and will keep IPIX SP compressed and severely undervalued. They will also continue to show fake volume. NR needs REAL shares so they will continue to try to get Longs to sell cheap. Remember the Shareholder Meeting vote of 140M yes votes or 90% of voted shares. This number is a proof point that a vast majority of IPIX investors are long and strong. They believe in IPIX’s products and direction and long term value. This proof point highlights the bogus volume that NR is trying to show. You need buyers AND sellers to complete a legit transaction. There are very few sellers so NR must continue to play their criminal games. Once Leo secures non-dilutive funding it is the start of Game-Over for the criminals. Once royalty revenue flows it is the END of the game for the criminals. In the meantime Long Term Investors will enjoy the ride knowing that short term SP is a mirage and our patience will be greatly rewarded as IPIX science continues to advance and milestones are met. Long term there will be great wealth for patient investors.
16
1
